Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma | BMC Cancer | Full Text

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma | BMC Cancer | Full Text

BMC Cancer

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma

• Yehyun Park,
• Beom Kyung Kim,
• Jun Yong Park,
• Do Young Kim,
• Sang Hoon Ahn,
• Kwang-Hyub Han,
• Jong Eun Yeon,
• Kwan Soo Byun,
• Hye Soo Kim,
• Ji Hoon KimEmail author and
• Seung Up KimEmail authorView ORCID ID profile

BMC Cancer201919:363

https://doi.org/10.1186/s12885-019-5495-6

©  The Author(s). 2019

• Received: 16 February 2018
• Accepted: 20 March 2019
• Published: 16 April 2019

Open Peer Review reports

Abstract

Background

Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE.

Methods

A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were included.

Results

Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first (median 43.7 vs. 21.5 months for mHAP-II, 35.2 vs. 10.2 months for mHAP, and 39.8 vs. 18.6 months for HAP; all P < 0.001) and the second rounds of TACE (38.6 vs. 17.2 months for mHAP-II, 30.0 vs. 8.5 months for mHAP, and 32.6 vs. 17.3 months for HAP; all P < 0.001). Sequential assessment of risk scores at the second TACE round was applied for patients with A-B class risk scores at the first TACE round, which further identified two subgroups of A-B and C-D class risk scores with different outcomes (median survival 40.6 vs. 19.6 months for mHAP-II, 31.2 vs. 16.9 months for mHAP, and 35.8 vs. 21.0 months for HAP; all P < 0.001). Compared with mHAP and HAP, mHAP-II showed the highest likelihood ratio (22.61 vs. 14.67 and 13.97, respectively), highest linear trend (24.43 vs. 19.67 and 14.19, respectively), and lowest Akaike information criteria value (1432.51 vs. 3412.29 and 2296.98, respectively).

Conclusions

All HAP-related risk scores dynamically predicted outcomes during repeated TACE. Sequential risk assessment using mHAP-II best identified optimal candidates for repeated TACE.

Keywords

• Hepatocellular carcinoma
• Trans-arterial chemoembolization
• Risk prediction
• Hepatoma arterial-embolization prognostic score